Esperovax Awarded $1M for Development of an Oral COVID-19 RNA Vaccine under the HHS Project NextGen Initiative
/PRNewswire/ -- Esperovax, a U.S.-based preclinical biopharmaceutical company and a BLUE KNIGHT™ resident company, is receiving an award for $ 1 M to further...
Slobodan Paessler Prnewswire Esperovax Robin Robinson Development Authority University Of Texas Medical Branch Biomedical Advanced Research
Source: prnewswire.com